Pharmacokinetics and pharmacodynamics of hydroxyurea

Clinical Pharmacokinetics

Volumn 34, Issue 5, 1998, Pages 347-358

  Gwilt, Peter R ^a   Tracewell, William G ^b  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^b MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CISPLATIN; CYTARABINE; DIDANOSINE; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE; BONE MARROW SUPPRESSION; CANCER; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; LEUKOPENIA; MICHAELIS MENTEN KINETICS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; STOMACH ULCER; STOMATITIS; TERATOGENESIS; TOTAL BODY WATER; URINARY EXCRETION; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANEMIA, SICKLE CELL; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; ANTISICKLING AGENTS; HUMANS; HYDROXYUREA; NUCLEIC ACID SYNTHESIS INHIBITORS;

EID: 0031923969     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834050-00002     Document Type: Review

References (76)

1. Dresler WFC, Stein R. Uber den hydroxhylarnstoff. Justus Liebigs Ann Chem Pharm 1869; 150: 242-52
2. Rosenthal F, Wislicki L, Kollek L. Uber die Beziehungen von schwersten Blutgiften zu Abbauprodukten des Eiweisses: ein Betrag zum Entstchungsmechanismus der perniziosen Anamie. Klin Wochenschr 1928; 7: 972-7
3. Stearns B, Losee KA, Bernstein J. Hydroxyurea: a new type of potential antitumor agent. J Med Chem 1963; 6: 201
4. Yarbro JW, Kennedy BJ, Barnum CP. Hydroxyurea inhibition of DNA synthesis in ascites tumor. Proc Natl Acad Sci U S A 1965; 53: 1033-5
5. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992; 19 (3 Suppl. 9): 1-10
6. Krakoff IH, Brown NC, Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res 1968; 28: 1559-65
7. Wright JA, Chan AK, Choy BK, et al. Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA sysnthesis. Biochem Cell Biol 1990; 68 (12): 1364-71
8. Stubbe J. Ribonucleotide reductases. Adv Enzymol Relat Areas Mol Biol 1990; 63: 3494-19
9. Lassmann G, Liermann B. ESR studies of structure and kinetics of radicals from hydroxyurea: an antitumor drug directed against ribonucleotide reductase. Free Radic Biol Med 1989; 6 (3): 241-4
10. Graslund A, Ehrenberg A, Thelander L. Characterization of the free radical of mammalian ribonucleotide reductase. J Biol Chem 1982; 257 (10): 5711-5
11. Elford HL, Wampler GL, vant Riet B. New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res 1979; 39: 844-51
12. Davidson JD, Winter TS. A method of analyzing for hydroxyurea in biological fluids. Cancer Chemother Rep 1963; 27: 97-110
13. Philips FS, Sternberg SS, Schwartz HS, et al. Hydroxyurea I. Acute cell death in proliferating tissues in rats. Cancer Res 1967; 27: 61-75
14. Fabricius E, Rajewsky MF. Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Etud Clin Biol 1971; 16 (7): 679-83
15. Tracewell WG, Trump DL, Vaughan WP, et al. Population pharmacokinetics of hydroxyurea in cancer patients. Cancer Chemother Pharmacol 1995; 35 (5): 417-22
16. Veale D, Cantwell BMJ, Kerr N, et al. Phase I study of hydroxyurea in lung cancer. Cancer Chemother Pharmacol 1988; 21 (1): 53-6
17. Havard J, Grygiel J, Sampson D. Determination by high-performance liquid chromatography of hydroxyurea in human plasma. J Chromatogr 1992; 584: 27-4
18. Villani P, Maserati R, Regazzi MB, et al. Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. J Clin Pharmacol 1996; 36: 117-21
19. Pujari MP, Barrientos A, Muggia FM, et al. Determination of hydroxyurea in plasma and peritoneal fluid by high-performance liquid chromatography using electrochemical detection. J Chromatogr B Biomed Sci Appl 1997; 694 (1): 185-91
20. El-Yazigi A, Al-Rawithi S. Analysis of hydroxyurea in capsules and aqueous solution and stability study with capillary gas chromatography and therminonic (N-P) detection. Pharm Res 1992; 9 (1): 115-8
21. Evered DF, Selhi HS. Transport characteristics of two carcinostatic compounds, hydroxyurea and hadacidin, with rat small intestine [abstract]. Biochem J 1972; 126: 26P
22. 14C. J Pharmacol Exp Ther 1965; 150 (2): 322-4
23. Tracewell WG, Vaughan WP, Gwilt PR. Pharmacokinetics of hydroxyurea in the rat [abstract]. Pharm Res 1992; 9 Suppl.: S260
24. Belt RJ, Haas CD, Kennedy J, et al. Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics and cell synchronization Cancer 1980; 46 (3): 455-62
25. Morgan JS, Creasey DC, Wright JA. Evidence that the antitumor agent hydroxyurea enters mammalian cells by a diffusion mechanism. Biochem Biophys Res Commun 1986; 134 (3): 1254-9
26. Blasberg RG, Patlack C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 1975; 195: 73-83
27. Beckloff GL, Lerner HJ, Frost D, et al. Hydroxyurea (NSC-32065) in biologic fluids: dose-concentration relationship. Cancer Chemother Rep 1965; 48: 57-8
28. Colvin M, Bono VH. The enzymatic reduction of hydroxyurea to urea by mouse liver. Cancer Res 1970; 30 (5): 1516-9
29. Andrae U. Evidence for the involvement of cytochrome P-450 dependent monooxygenase (S) in the formation of genotoxic metabolites from N-hydroxyurea. Biochem Biophys Res Commun 1984; 118 (2): 409-15
30. Fishbein WN, Carbone PP. Hydroxyurea: mechanism of action. Science 1963; 142: 1069-70
31. Van Den Berg CL, McGill JR, Kuhn JG, et al. Pharmacokinetics of hydroxyurea in nude mice. Anticancer Drugs 1994; 5 (5): 573-8
32. Creasey WA, Capizzi RL, DeConti RC. Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065). Cancer Chemother Rep 1970; 54 (3): 191-4
33. Newman EM, Carroll M, Akman SA, et al. Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. Cancer Chemother Pharmacol 1997; 39: 254-8
34. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992; 79 (10): 2555-65
35. Collins JM. Pharmacological rationales for regional drug delivery. J Clin Oncol 1984; 2: 498-504
36. Guyton AC. Textbook of medical physiology. 8th ed. Philadelphia: WB Saunders, 1991; 186
37. Schilsky RL, Ratain JM, Vokes EE, et al. Laboratory and clinical studies of biochemical modulation by hydroxyurea. Semin Oncol 1992; 19 (3 Suppl. 9): 84-9
38. Rauscher F, Cadman E. Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxy urea and effect on 1-β-D-arabinofuranosylcytosine metabolism and cytotoxicity. Cancer Res 1983; 43: 2688-93
39. Kubota M, Takimoto T, Tanizawa A, et al. Differential modulation of 1-beta-D-arabinofuranosylcytosine metabolism by hydroxyurea in human leukemic cell lines. Biochem Pharmacol 1988; 37 (9): 1745-9
40. Schilsky RL, Williams SF, Ultmann JE, et al. Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkins lymphoma. J Clin Oncol 1987; 5 (3): 419-25
41. DeGramont A, Louvet C, Varette C, et al. Reversal of resistance to high-dose folinic acid (LV) and 5-fluorouracil (5-FU) in metastatic colorectal cancer by hydroxyurea [abstract]. Proc Am Soc Clin Oncol 1992; 11: 178
42. Heidelberger C, Danenberg PV, Moran RG. Fluorinated pyrimidines and their nucleosides. Adv Enzymol Relat Areas Mol Biol 1983; 54: 58-119
43. Li JC, Kaminskas E. Progressive formulation of DNA lesions in cultured Ehrlich ascites tumor cells treated with hydroxyurea. Cancer Res 1987; 47 (11): 2755-8
44. Minford J, Kerrigan D, Nichols M, et al. Enhancement of the DNA breakage and cytotoxic effects of intercalating agents by treatment with sublethal doses of 1-β-D-arabinofuranosylcytosine or hydroxyurea in L1210 cells. Cancer Res 1984; 44 (12 Pt 1): 5583-93
45. Ratain MJ, Schilsky RL, Wojack BR, et al. Hydroxyurea and etoposide: in vitro synergy and phase 1 clinical trial. J Natl Cancer Inst 1988; 80 (17): 1412-6
46. Swinnen LJ, Barnes DM, Fisher SG, et al. 1-β-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum (II) and modification of platinum-induced DNA interstrand cross-linking. Cancer Res 1989; 44 (6): 1383-9
47. Christen RD, Shalinsky DR, Howell SB. Enhancement of the loss of multiple drug resistance by hydroxyurea. Semin Oncol 1992; 19 (3 Suppl. 9): 94-100
48. Snapka RM, Varshavsky A. Loss of unstably amplified dihydrofolate reductase genes from mouse cells is greatly accelerated by hydroxyurea. Proc Natl Acad Sci U S A 1983; 80 (24): 7533-7
49. Von Hoff DD, Waddelow T, Forseth B, et al. Hydroxyurea accelerates loss of extrachromosomally amplified genes from tumor cells. Cancer Res 1991; 51 (23 Pt 1): 6273-9
50. Kennedy BJ. Hydroxyurea therapy in chronic myelogenous leukemia. Cancer 1972; 29 (4): 1052-6
51. Sharon R, Tatrsky I, Ben-Arieh Y. Treatment of polycythemia vera with hydroxyurea. Cancer 1986; 57 (4): 718-20
52. Ariel IM. Therapeutic effects of hydroxyurea: an experience with 118 patients with inoperable solid tumors. Cancer 1970; 25 (3): 705-14
53. Carter SK, Wasserman TH. The chemotherapy of urologic cancer. Cancer 1975; 36: 729-47
54. Mundy AR. A pilot study of hydroxyurea in hormone 'escaped' metastalic carcinoma of the prostate. Br J Urol 1982; 54: 20-5
55. Hussey DH, Abrams JP. Combined therapy in advanced head and neck cancer: hydroxyurea and radiotherapy. Prog Clin Cancer 1975; 6: 79-86
56. Hreshchyshyn MM, Aron BS, Boronow RC, et al. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Im J Radiat Oncol Biol Phys 1979; 5: 317-22
57. Piver MS, Vongtama V, Emrich LJ. Hydroxyurea plus pelvic radiation versus placebo plus pelvic radiation in surgically staged stale IIIB cervical cancer. J Surg Oncol 1987; 35 (2): 129-34
58. Layton AM, Sheehan-Dare RA, Goodfile MJ, et al. Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol 1989; 121 (5): 647-53
59. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266: 801-5
60. Griffith KM. Hydroxyurea (NSC-32065): results of a phase I study. Cancer Chemother Rep 1964; 40: 33-6
61. Vaughan WP, Kris E, Vose J, et al. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractors intermediate-grade and high-grade malignant lymphoma. J Clin Oncol 1995; 13 (5): 1089-95
62. Donehower RC. Hydroxyurea. In: Chabner B, editor. Pharmacologic principles of cancer treatment. Philadelphia: WB Saunders, 1982: 269-75
63. Wilson JG, Scott WJ, Riller KJ, et al. Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys. Teratology 1975; 11 (2): 169-78
64. Ford SS, Shackney SE, Lethal and sublethal effects of hydroxyurea in relation to drug concentration and duration of drug exposure in sarcoma 180, in vitro. Cancer Res 1977; 37 (8 Pt 1): 2628-37
65. Moran RE, Straus MJ. Cytokinetic analysis of L1210 leukemia after continuous infusion of hydroxyurea in vivo. Cancer Res 1979; 39 (5): 1616-22
66. Blumenreich MS, Kellihan MJ, Joseph UG, et al. Long-term intravenous hydroxyurea infusions in patients with advanced cancer: a phase I trial. Cancer 1993; 71 (9): 2828-32
67. Brown PC, Tlsty TD, Schimke RT. Enhancement of methotrexate resistance and dihydrofolate reductase gene amplification by treatment of mouse 3T6 cells in hydroxyurea. Mol Cell Biol 1983; 3 (6): 1097-1107
68. Dover GJ, Humphries RK, Moore JG, et al. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood 1986; 67 (3): 735-8
69. Gao WY, Johns DG, Chokekijchai S, et al. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci U S A 1995; 92: 8333-7
70. Malley SD, Grange JM, Hamedi-Sangsari K, et al. Synergistic anti-human immunodeficiency virus type 1 effect hydroxamate compounds with 2,3-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci U S A 1994; 91: 11017-21
71. Giacca M, Zanossi S, Comar M, et al. Treatment of human immunodeficiency virus intection with hydroxyurea: virologic and clinical evaluation. J Infect Dis 1996; 174: 204-9
72. Simonelli C, Nasti G, Vaccher E, et al. Hydroxyurea treatment in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: 462-4
73. Biron F, Lucht F, Peyramond D, et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 36-40
74. Vila J, Biron F, Nugier F, et al. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection. Lancet 1996; 348 (9021): 203-4
75. Montaner JSG, Zala C, Conway B, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving: chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997; 175: 801-6
76. Malley SD, Grange JM, Hamedi-Sangsari F, et al. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds [abstract]. Lancet 1994; 343: 1292